FDA Inspection 1165020 — Xlear Inc.

Xlear Inc. — FEI 3010166224

The FDA completed an inspection of Xlear Inc. on March 18, 2022 in American Fork, UT. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 9 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 18, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
American Fork, UT (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
144821 CFR 211.111Establishment of time limitations
154021 CFR 211.125(a)Strict control not exercised over labeling issued
180321 CFR 211.84(b)Representative Samples Criteria
192621 CFR 211.166(b)Adequate number of batches on stability
194221 CFR 211.180(e)Records reviewed annually
360321 CFR 211.160(b)Scientifically sound laboratory controls
431321 CFR 211.84(c)(6)Containers Marked to Show Samples Taken
440021 CFR 211.186(b)(8)Description of containers, labels, et. al.